In the past decade, we have witnessed significant advances in ex vivo hematopoietic stem cell culture expansion, progressing to the point where clinical trials are being designed and conducted. Preclinical milestone investigations provided data to enable expansion of portions of hematopoietic grafts in a clinical setting, indicating safety and feasibility of this approach. Data derived from current clinical trials indicate successful reconstitution of hematopoiesis after myeloablative chemoradiotherapy using infusion of ex vivo-expanded perfusion cultures. Future avenues of exploration will focus upon refining preclinical and clinical studies in which cocktails of available cytokines, novel molecules and sophisticated expansion systems will explore expansion of blood, marrow and umbilical cord blood cells.
In the past decade, considerable progress has been made in our understanding of human hematopoietic stem cell (HSC) biology.
1, 2 In parallel, advances in the supportive care of patients undergoing autologous or allogeneic stem cell transplantion have significantly reduced the mortality rates associated with these procedures, resulting in an increase in the proportion of potentially eligible patients. 3 Nevertheless, further progress has been hindered by the profound and often prolonged pancytopenia associated with myelosuppressive conditioning, the toxicity of the conditioning regimens, graft-versus-host disease (GVHD), a myriad of opportunistic infections, and relapse of the original disease. Unfortunately, patients with diseases otherwise amenable to allogeneic HSC transplantation often lack a suitably matched donor. Efforts to increase the pool of available donors have led to clinical trials evaluating alternative donor sources including volunteer unrelated, mismatched related, and unrelated umbilical cord blood (UCB). [4] [5] [6] [7] [8] [9] [10] While sometimes successful, these procedures are affected by an even higher risk of the transplant-associated complications.
Recently, the dose of cells transplanted and patient outcome have been shown to correlate positively. 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] This relation holds for both the autologous and allogeneic transplant settings whether the variables analyzed include total nucleated cell dose, CD34+ cell dose, or hematopoietic progenitor cell dose. As a logical extension of these findings, it has been hypothesized that the capacity to expand in vitro the quantity of hematopoietic stem and progenitor cells available for transplantation would enhance hematopoietic engraftment, reduce the risk of infection, and as a result increase the number of potentially available alternative donors. Moreover, the successful ex vivo expansion of hematopoietic stem and progenitor cells could be exploited for a variety of clinical applications, including the purging of contaminating tumor cells, increasing the number of cells available for genetic modification, and the generation of large quantities of immunologically reactive cells (T cells, natural killer cells, and dendritic cells) for adoptive immunotherapeutic purposes (Table 1) . However, as many investigators begin to consider ex vivo HSC expansion for clinical applications, a number of questions have emerged (Table 2) . Successful clinical application of expanded hematopoiesis will clearly require a greater understanding of human stem cell biology, identification of the proper balance and concentration of the available cytokine cocktails for ex vivo culture, and hastening the slow pace of clinical trials. In this review, we discuss the past, current, and future strategies of hematopoietic progenitor cell expansion, point out current pitfalls, and highlight potential opportunities.
The path to the present
In the late 1980s several advances were made, which suggested that the ability of HSC to proliferate without loss of self-renewal might be harnessed ex vivo. Although the most concrete goal that surfaced was the controlled production of mature blood cells for transfusion therapy, the magnitude of cell production required was so large that the efficiency requirements for a culture system that could produce red cells or platelets for clinical use immediately was seen as overly daunting. On the other hand, expansion of immature compartments, including hematopoietic stem and progenitor cells, sufficient for clinical application, seemed within reach; perhaps expansion to a degree as little as 20-100 fold would be useful.
Three related observations drove the field forward. Elegant morphologic studies by Gail and Brian Naughton demonstrated that restoration of a simile of the in vivo three-dimensional bone marrow microenvironment with nylon mesh, allowing stromal cell tethering across open space between attachments, encouraged the production of mature blood cells of all lineages, including red blood cells. 20 Unfortunately, while this was qualitatively a significant improvement over the first generation of hematopoietic cell cultures performed on flat dishes, they were only effective in small culture systems. Multilayer, large-scale cultures built on such nylon meshes proved very difficult to oxygenate and perfuse, such that very few mature blood cells or progenitor cells could be produced. Also pursuing the notion of in vivo mimicry, Caldwell et al 21 and Schwartz et al 22, 23 demonstrated that slow perfusion and local oxygenation of flat hematopoietic cultures would allow stem cell survival with 10-20-fold progenitor cell expansion. The flat architecture used by Schwartz et al could be manufactured to larger scales, so that sufficient numbers of cells for clinical trials could be produced in one or two closed culture vessels. [21] [22] [23] Finally, Haylock et al showed that, if sufficient quantities of interleukin-1b (IL-1), IL-3, IL-6, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage-CSF (GM-CSF), and stem cell factor (SCF) were added to cultures of CD34+-enriched peripheral blood progenitor cells, progenitor cell expansions of 50-fold or more could be achieved. 24 These preclinical data suggested that the incorporation of multiple stem cell active cytokines into systems that foster cell survival and expansion potentially could be adapted for clinical use.
Three parallel areas of investigation followed on the heels of these tantalizing studies. First, literally hundreds of laboratories attempted to maximize the efficiency of purified human progenitor cell cultures, by beginning with more highly purified starting cell (CD34+ or CD34+lin-) populations, adding more or different cytokines or both. However, these studies were rarely accompanied by assays of true stem cell repopulating cell numbers, largely because of the difficulty of manipulating the human-to-NOD/SCID or SCID/hu transplant assays quantitatively. Second, careful studies in murine stem cell transplants indicated that SCF, flt-3 ligand, and thrombopoietin (TPO) likely were the most important cytokines for promoting true stem cell expansion. [25] [26] [27] [28] [29] [30] [31] [32] Third, clinical trials began using ex vivo expanded hematopoietic cells to augment or replace standard autografts, and later allografts.
Clinical trials of ex vivo expansion
By and large, the published clinical trials have sought to expand the number of short-term repopulating cells (STRC) and mature cells with the goal of abrogating or shortening the period of profound pancytopenia observed following high-dose chemotherapy or chemoradiotherapy. Studies to date have not addressed whether true long-term repopulating cells (LTRC) can be expanded and transfused to shorten the period of pancytopenia and improve the overall rate of engraftment. This distinction is critical since at present there are no convincing data to support the notion that true HSC with LTRC potential can be expanded substantially in culture. 2, 33, 34 The trials to date have been designed to address two distinct but related questions: (1) If a dose of cells sufficient to provide a standard autograft is cultured ('expanded') ex vivo and used as a sole source of hematopoietic support, will the patients engraft? (2) Can neutrophil nadir, platelet nadir, or both be Table 3) . One of the earliest studies involving ex vivo-expanded cells was reported by Naparstek et al 35 in patients with hematologic malignancies receiving allogeneic bone marrow transplants. Following conditioning, patients received two-thirds of the donor bone marrow unmanipulated on day 0 and one-third of the bone marrow following culture in GM-CSF and IL-3 for 4 days. No improvement in neutrophil recovery was observed and few data were reported as to the results of the ex vivo culture, such as fold expansion of colony-forming units granulocytemacrophage (CFU-GM) or total nucleated cells.
Later, Brugger et al 36 transfused 10 cancer patients with chemotherapy and G-CSF-mobilized autologous CD34-selected cells cultured in RPMI, 2% autologous plasma, SCF, interleukin-1b, interleukin-3, interleukin-6, and erythropoietin (EPO) for 12 days. Six of the 10 patients received expanded cells as the sole source of hematopoietic rescue. Although all patients had rapid and sustained engraftment, recovery kinetics did not differ from historic controls. Of some concern, no late follow-up was reported and the publication was recently retracted. 37 Williams et al 38 expanded cells in PIXY321 (a GM-CSF/IL-3 fusion protein) for 12 days and transfused these autologous cells into nine patients with metastatic breast cancer. The expanded cells were obtained following mobilization with chemotherapy plus G-CSF. The cells were subsequently CD34 selected with an immunomagnetic device and cultured in serum-free X-VIVO 10 medium (BioWhittaker, Walkersville, MD, USA) supplemented with 1% human serum albumin and 100 ng/ml PIXY321. An overall median 26-fold cellular expansion was observed during the 12-day culture and the median number of expanded cells infused was 44.6 Â 10 6 /kg. No toxicity attributable to the expanded cells was observed, and clinical benefit was seen. In another trial reporting the use of cultured cells combined with unmanipulated PBPC for hematopoietic rescue, 10 patients with nonmyeloid malignancies received expanded CD34+ cells from cryopreserved PBPC. 39 Following thawing, cells were CD34 selected using the Isolex 300I device (Nexell Inc., Irvine, CA, USA) and cultured for 8 days in medium supplemented with SCF, IL-3, IL-6, IL-1b, and EPO. The mean increase in total cell number (21-fold) and CFU-GM (139-fold) were substantial, there were no adverse events related to the infusion of expanded cells, and engraftment was comparable to historical controls receiving only unmanipulated grafts. The results of a second study by the same group were sobering. Holyoake et al 40 infused expanded autologous CD34-selected cells as the sole source of hematopoietic rescue to four patients given a myeloablative conditioning regimen. Prolonged pancytopenia and failure of engraftment was observed in all four patients receiving only the expanded cells. Each patient had to be rescued with an autologous 'back-up' stem cell collection. These results suggested that following a myeloablative conditioning regimen, hematopoietic cells cultured under these stroma-free conditions may be insufficient to support the maintenance of cells with both short-and long-term engraftment capacities.
Four recently published trials are more encouraging. [41] [42] [43] [44] McNiece et al 43 expanded CD34-selected G-CSF-mobilized autologous peripheral blood hematopoietic cells in a stroma-free culture, which included defined media (IMDM, 1% human serum albumin, recombinant human transferrin, Amgen Inc., Thousand Oaks, CA, USA) supplemented with SCF, megakaryocyte growth and development factor (MGDF), and G-CSF (all at 100 ng/ml; Amgen). The cells were expanded in static culture for 10 days in Teflon bags (American Fluoroseal, Gaithersburg, MD, USA) and reinfused together with unexpanded CD34-selected cells. In a second cohort of 10 patients, only ex vivo-expanded cells were infused. Compared to historic controls, neutrophil engraftment was hastened by 3-4 days, although there was no effect on platelet recovery. Other recent studies suggest that mobilized peripheral blood (MPB) cells placed in stroma-free expansion cultures, if provided in sufficiently high numbers, may be useful for shortening neutropenic and thrombocytopenic nadirs when supplementing unmanipulated peripheral (PB) grafts. Paquette et al 41 performed autografts in breast cancer patients with unmanipulated PB cells containing 5 Â 10 6 CD34+ cells/kg supplemented with increasing doses of unseparated PB cells cultured in G-CSF, SCF, and MGDF for 9 days. The study analyzed the impact of varying the density of cells initially expanded. The fold expansion of CD34 cells following culture was inversely proportional to the initial cell density. A dosedependent shortening in both neutrophil and platelet nadirs was observed, with 29% of the patients having neutrophil nadirs o3 days, and 38% experiencing no neutropenic fevers. This was significantly improved in comparison to 78 historical control patients. Of note, platelet engraftment was improved in the recipients of expanded cells. However, it should also be noted that this is the only trial in which cells were mobilized and collected following a combination of G-CSF and SCF. The influence of SCF on the engraftment function of the mobilized cells is unclear. Reiffers et al 42 similarly transplanted supplemented PB autografts in patients with multiple myeloma, but using only 2 Â 10 6 unmanipulated CD34+ cells/kg and submitting the remainder of the leukapheresis to expansion culture prior to infusion. As a result, many more progenitor cells derived from the expanded cells were infused than from the unmanipulated PB collection. Neutrophil nadirs in these patients were extremely short, averaging only 2 days with neutrophils o500/ml. Validation of this preliminary report would represent a major step in the realization of nadir ablation by expanded hematopoietic cell supplementation.
Current evidence supports the concept that localization of hematopoiesis to marrow involves developmentally regulated adhesive interactions between primitive lymphohematopoietic cells and marrow stroma. In vitro and in vivo studies support the contention that stromal cells provide a rich environment of signals (cytokines, extracellular matrix proteins, adhesion molecules) that control proliferation, survival, and differentiation of hematopoietic progenitor and stem cells. 2, 45 Two groups of investigators began to incorporate the stromal components into the expansion cultures. 44, 46 These two studies examined whether small aliquots of steady-state bone marrow can be harvested, expanded ex vivo, and used as the sole source to support hematopoietic recovery after high-dose chemotherapy. Both studies utilized a perfusion-based stromal cellcontaining expansion device that employed frequent medium, cytokine, and gas exchange. All patients received G-CSF following infusion of expanded cells. The publication by Stiff et al 44 inoculated approximately 10% of a standard bone marrow mononuclear cell dose into perfusion culture vessels. When used as the sole source of hematopoietic support, this graft reconstituted neutrophil count after a median 16 (range 13-24) days and platelet count at a median of 24 (range 19-45) days. Engelhardt et al 46 found almost precisely the same results in a trial of similar design; neutrophil nadirs ranged from 9 to 18 (median 16) days and platelet nadirs spanned 16-49 (median 23) days. These findings are similar to unexpanded bone marrow, but slower than MPB. Therefore, the evidence thus far supports the ability of ex vivo-cultured bone marrow mononuclear cells, under defined environments, to maintain its engraftment potential after a one-log expansion. An added benefit of such cultures is that many different tumor types, including breast cancer and lowgrade lymphoma, may die within these cultures, thereby providing tumor cell purging as well. 47 On the other hand, there is as yet no convincing evidence that supplementation of an autograft with ex vivo-expanded hematopoietic cells, at least under current culture conditions with the cytokine combinations available, can completely eliminate hematopoietic nadirs.
In all of these clinical trials, the relative contributions to hematopoietic recovery of expanded vs endogenous cells cannot be accurately assessed since autologous cells were used and no gene marking was employed. The studies reported by Paquette et al, 41 Reiffers et al, 42 and McNiece et al, 43 however, suggest that expanded mature or postprogenitor cells may make contributions to early hematopoietic recovery. On the other hand, patients received large doses of cells generated in culture, yet these subjects still experienced profound aplasia; such results are somewhat disappointing and suggest that the culture conditions may affect the functional properties of at least a fraction of the cells infused. Earlier gene marking studies suggested that ex vivo culture may inhibit the capacity of in vitrodefined progenitor cells to contribute to early engraftment. 48, 49 Recent studies in murine and nonhuman primate models strongly suggest the acquisition of functional defects acquired by progenitor cells following in vitro culture. [50] [51] [52] [53] [54] [55] Another complication pervading these early clinical investigations was their use of suboptimal combinations of stem cell-active cytokines in the hematopoietic cultures. [40] [41] [42] [43] [44] Implementation of novel and potentially advanced technology into expansion has been delayed because of many factors including FDA review, obtaining corporate agreements, and other pragmatic but existing hurdles. Several laboratories have developed assays for long-term culture-initiating cells (LTC-IC) or cobblestone area forming cells (CAFC) performed in limiting dilution as a surrogate human stem cell assay. 27, 29, 30 Such assays detect cells capable of producing colony-forming cells (LTC-IC) or tight clusters of blast cells (CAFC) after at least 5 weeks of stromal-based culture. These assays are useful to monitor the expansion of primitive hematopoietic cells in culture. None of the clinical trials reported to date have utilized combinations of the cytokines required for maximal progenitor cell and LTC-IC expansion in vitro, nor have been combined with the stromal-based perfusion culture techniques that have shown the best preclinical results for LTC-IC survival and expansion. 56 Finally, except for the study by Holyoake et al 40 in which delayed engraftment was observed, none of the other trials used conditioning regimens that would be considered truly marrow-ablative. These flaws weaken an assessment of the long-term engraftment capacity of the expanded cells transplanted in these trials. The cumulative results of the published marrow and MPB ex vivo expansion trials are presented in Table 4 .
On a more pragmatic level, it remains to be seen whether progenitor cell expansion in support of autologous transplantation is a useful clinical target. Is it worth the expense and resource utilization to expand cells to achieve a marginal improvement in hematopoietic recovery, particularly when the risk of death during the early phase of pancytopenia after autografting is less than 1% in many centers? Further, it is unclear whether a similar strategy would be beneficial in the HLA-matched allogeneic transplant setting given that similar reductions in the duration of neutropenia have been observed simply infusing G-CSF-mobilized donor granulocytes. 57, 58 Finally, the recent demonstration that reduced-intensity conditioning in combination with donor MPB significantly may reduce the duration of pancytopenia after allogeneic transplantation suggests that a graft augmentation strategy in this setting may be unnecessary. 3, 59, 60 Notwithstanding, several potentially useful clinical targets including UCB expansion as well as expansion of hematopoietic cells for genetic modification remain, and even modest improvements in these areas could be clinically meaningful.
Defining new clinical targets: UCB
UCB cells are an effective alternative donor source for patients with hematological disorders requiring stem cell transplantation. 9, 10, 17 Overall survival in pediatric recipients is comparable to that observed following volunteer unrelated marrow transplantation. 5, 61 Both the rates and kinetics of hematopoietic engraftment, however, are inferior to unrelated donor marrow and a significant proportion of patients die because of opportunistic infections during the period of prolonged neutropenia. 5, 10, 12, 17, 61, 62 Although the feasibility of UCB transplantation has been demonstrated in adults, the periods of pancytopenia are even longer and there is a clear relation between the dose of UCB cells transplanted and overall outcomes. 10 Given the fact that at least one log fewer of nucleated and CD34+ cells are infused compared to conventional allografts as well as a much greater degree of mismatching at HLA loci, it is remarkable that engraftment occurs at all. Most heavily pretreated adult patients simply do not tolerate such a prolonged period of neutropenia, and therefore studies designed to improve the kinetics of hematopoietic engraftment are imperative. One approach to increase the number of hematopoietic cells transplanted involves combining multiple unrelated cord blood grafts. 9, 63 It remains to be determined whether this technique will facilitate or hinder recovery, since immune interactions between infused units and the recipient conceivably could delay rather than augment donor cell engraftment. Alternatively, the in vitro expansion of all or a portion of a single UCB graft is being studied. Whether ex vivo-cultured allogeneic cells can suffice for long-term reconstitution has not yet been defined.
UCB cells, which demonstrate the largest progenitor cell and LTC-IC expansion potential in vitro, have only recently been the subject of augmentation studies (Table 5) . Three trials evaluating the combination of unmanipulated cells with ex vivo-expanded UCB grafts were reported in preliminary fashion, but are difficult to interpret because of the study designs. [64] [65] [66] In all three studies reported, expanded cells were always infused with unmanipulated cells. Although one study suggested a potential hastening of platelet engraftment, 65 the others showed no benefit. 64, 66 One study involved the use of a static culture system in defined media, while the other two used a perfusion culture expansion system. None of these systems have been demonstrated to expand true LTRC and therefore the goal of these trials once again was to expand mature cells and STRC with the hope of improving early engraftment. The Table 5 Results from pilot trials of ex vivo expansion using unrelated cord blood Clinical application of hematopoietic progenitor cell expansion SM Devine et al relative contributions of the unexpanded and expanded cells to hematopoietic recovery cannot be assessed in these trials. Pecora et al 67 published a report of two adult CML patients who experienced stable engraftment after receiving the major portion (83 and 89%) of a UCB graft as unmanipulated cells, while the remaining cells were infused after 12 days in ex vivo culture. The relative contributions of the expanded and unmanipulated cells to long-term recovery were impossible to determine because most of the infused CFU-GM were derived from expanded cells, whereas the majority of CD34+Lin-cells arose from the unexpanded portion of the graft. To date, there is no convincing evidence that current approaches to ex vivo UCB expansion will lead to definable improvements in clinical outcomes.
Additional biologic advantages of UCB
Despite these caveats, the tremendous potential of UCB transplantation for the correction of a variety of hematological disorders warrants further studies of ex vivo UCB expansion. Preclinical studies suggest significant ontogenyrelated differences in the in vivo repopulating potential of various human HSC sources. 31, [68] [69] [70] [71] [72] [73] There appears to be a continuum of engraftment capacity with greatest potential residing in fetal liver cells followed by UCB, adult marrow, and lastly MPB.
2,70,74,75 UCB possesses a greater capacity for expansion of primitive progenitors in response to various early-acting cytokines in comparison with adult marrow or MPB. 56, 70, [74] [75] [76] [77] [78] [79] [80] The functional capacity of HSC, as assessed by the ability to engraft in various xenogenic murine transplant models, is greater with UCB in comparison to marrow or MPB. 30, 70, 75, 78 This finding may relate more to intrinsic differences in replicative history or cell cycle status than to differences in homing capacity, as UCB may possess a limited capacity for self-renewal division in culture. 31, 56, 73, 75, 81, 82 In competitive repopulation assays, UCB possesses superior engraftment capacity compared to adult marrow. 78 Thus, preclinical data suggests that UCB represents an optimum clinical target for ex vivo expansion strategies.
Current bottlenecks to clinical development
A significant hindrance to efficient in vitro culture system development has been the lack of reliable surrogate markers for HSC function. 33 Although surface phenotype has been a useful surrogate means to define a population of cells within adult marrow or MPB enriched for HSC, there is an apparent dissociation between phenotype and function after exposure to cytokines in vitro. 79, 83, 84 Under normal conditions, the CD34+, lineage negative (CD34+Lin-) or CD34+CD38À phenotype defines a population of human hematopoietic cells enriched for HSC.
1,2 Such markers, however, have been shown to be an unreliable surrogate for expansion of repopulating cells after culture. 33 Further complicating matters is the apparent disparity between surrogate in vitro assays of hematopoietic progenitor and stem cell function and repopulating potential. Progenitor cell assays such as the CFU-GM have been useful to assess the quality of unexpanded grafts.
CFU-GM are distinct from the cells responsible for marrow repopulation, and therefore the prediction of repopulating potential based on ex vivo CFU-GM expansion will likely overestimate the functionality of the graft. 33, 48, 85, 86 Other surrogate assays of primitive human hematopoietic progenitor cells such as the LTC-IC and CAFC may not accurately portray the expansion of an LTRC, as demonstrated in the NOD/SCID mouse. 85 Therefore, the demonstration of 'expansion' of LTC-IC or CAFC after culture does not necessarily connote expansion of true hematopoietic repopulating cells, including HSC.
Many studies suggest that in vitro culture of any duration leads to the acquisition of an engraftment defect, related to changes in the intrinsic program of the cells exposed to cytokines or to the development of a marrow homing defect. Studies performed in rodent and nonhuman primate models provide clear evidence of an engraftment defect following ex vivo expansion. 50, 52, 55, 83, 87 Recent investigations suggest that this effect may be due, in part, to the downregulation of various cellular adhesion molecules, beta integrins, or chemokine receptors crucial for homing of stem cells back into the bone marrow microenvironment following intravenous infusion. 32, 55, [88] [89] [90] [91] [92] [93] Moreover, it is presently unclear whether the cytokine cocktails used in current expansion protocols promote expansion, maintenance, or potentially apoptosis of HSC during culture or shortly following in vivo transfer. If HSC are prone to replicative senescence, it is possible that the culture will lead to the generation of 'exhausted' progeny and diminished functional capacity. 33, 53 Whether in vitro-cultured cells require continuous exposure to exogenous cytokines after transplantation is unclear, but data in baboons suggest this maneuver will be required to optimize hematopoietic recovery. 94 The appropriate combination of exogenous cytokines for this purpose is unknown and clinical trials are hindered by a lack of reagents due, in part, to commercial considerations.
Recent data also suggest a relation between the replicative history of an HSC and its engraftment capacity. All sources of HSC may possess some limited capacity for self-renewal. Both fetal liver and UCB appear capable of undergoing at least some self-renewal divisions while retaining engraftment capacity in contrast to the more limited repopulating capacity of adult marrow and MPB following self-replication. 2, 32, 33, 68, 69, 72, [95] [96] [97] There may also be ontogeny-associated differences in response to cytokine combinations, and therefore the optimal combination for one source of HSC may not be optimal for a different source. 73 Further, the retention or reacquisition of cell cycle quiescence following culture may be required to retain repopulating capacity; cells that have entered G 1 after cytokine exposure may be depleted of the engraftment capacity. 93, [98] [99] [100] [101] The phase of the cell cycle engaged at the time of transplantation therefore may critically affect homing and engraftment. Recent studies suggest that this effect may be reversible. 100 In summary, numerous questions abound regarding the functional effects of in vitro culture, which will require delineation in preclinical systems in order to ensure the likelihood of success clinically.
Where do we go from here?
The engraftment of ex vivo-expanded HSCs requires efficient homing, survival, in vivo expansion, and retention of multilineage differentiative capacity. Expansion requires conditions that induce self-renewal divisions and minimal apoptosis, differentiation, or loss of in vivo repopulating capacity. To date, such an artificial environment has not been achieved consistently, and therefore the identification of signals and factors important for activating HSC selfrenewal divisions without differentiation are crucial (Table 6 ). To improve the engraftment capacity of small grafts such as UCB, expansion of LTRC will likely be required. 2 If successful, this would improve both early and late engraftments as HSCs, when given in sufficient quantity, contribute to both short-and long-term engraftments in mice. [102] [103] [104] This concept recently was proven in clinical trials involving high-speed sorting and transplantation of cells defined by a primitive hematopoietic phenotype. 105, 106 Resources should be allocated towards the development of in vitro systems designed to expand LTRC. These culture conditions then could be studied first in xenogeneic transplantation models and then optimally in large animal models before being taken for clinical trials. Sufficient evidence suggests the potential to improve culture conditions and to enhance engraftment capacity of ex vivocultured cells. 107 For instance, Ueda et al 82 used a combination of early acting cytokines together with a complex of interleukin-6 and soluble interleukin-6 receptor to upregulate CXCR4 expression and therefore improve cell homing ability. Improved capacity to engraft NOD/ SCID mice was demonstrated under these culture conditions. Other strategies worthy of pursuit include targeting of antiapoptotic factors or the delta/jagged receptor interaction. [108] [109] [110] Another interesting approach involves copper chelation, as this element promotes hematopoietic differentiation in vitro.
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Clinical trials designed to combine chelation in combination with ex vivo cytokine exposure are underway.
Additionally, Takatoku et al 121 noted retention of engraftment capacity if activating cytokines are combined with cell cycle inhibition in order to prevent dividing cells from committing to lineage differentiation. Alternative strategies include the isolation of novel cytokines with the ability to amplify pluripotent stem cells, and development of soluble intracellular cell cycle activators or inhibitors that reversibly increase stem cell symmetric cycling and therefore directly increase stem cell numbers. Candidates might include antisense oligonucleotide or RNA interference inhibition of p21 or p27, as well as soluble inhibitors of transcription factors that suppress the transcription of HOX genes that stimulate stem cell cycling. 112, 113 Of note, treatment with reversible modulators of stem cell cycling raises concerns about inducing abnormally proliferative stem cells that could lead to the development of leukemia. Hence, such treatments must be studied in preclinical animal models before initiating clinical trials.
Efforts to recreate the in vivo hematopoietic microenvironment in culture systems have led to the generation of stromal cell lines from the aorto-gonado-mesonephros region, fetal liver, and bone marrow. 50, 91, 114 Postnatal human marrow contains a second stem cell, the mesenchymal stem cell (MSC), that gives rise to osteoblasts, chondrocytes, adipocytes, and myelosupportive stroma. 115, 116 MSCs express adhesive ligands and soluble factors critical for hematopoiesis, and have been demonstrated to support hematopoiesis in vitro. 115 Efforts to expand UCB grafts in combination with expanded MSC are ongoing and preliminary data are encouraging. 117 Other culture conditions designed to remove cells that might inhibit the expansion of repopulating cells in a dynamic system are being pursued. 118 Finally, human embryonic stem cells can be induced to differentiate into hematopoietic cells 119, 120 . If ethical and regulatory issues can be addressed successfully, these cells may become a useful source of HSC with LTRC potential.
The past two decades have demonstrated that through the extraordinary efforts of cell and molecular biologists, bioengineers, and clinical investigators, at least some of the proliferative potential of HSCs have been harnessed for clinical therapy. Present evidence suggests that hematopoietic augmentation strategies may able to significantly reduce postchemotherapy nadirs. Clinical trials based on the most promising preclinical data should be pursued as long as the target is appropriate and the study end points are well-defined. Each source of HSCs (BM, MPB, UCB) has its own, unique biologic properties in vitro as well as clinical efficacy in vivo, such that each tissue requires its own thoughtful study. True clinically useful stem cell expansion strategies that would allow the unlimited use of very small numbers of stem cells for full, rapid hematopoietic reconstitution await further preclinical study. Future investigations hopefully will provide exponential expansion of stem cells for tissue repair in hematology and other disciplines. 
